

DATASHEET

Version 20181206

ENA78/CXCL5(9-78 a.a.), Human**Cat. No.:** Z03271-5**Size:** 5.0 ug**Synonyms:** Epithelial Neutrophil Activating Peptide-78, CXCL5, ENA-78**Description:**

Epithelial cell derived neutrophil activating peptide (ENA78) also known as C-X-C motif chemokine 5 (CXCL5), is a small cytokine belonging to the CXC chemokine family. It is produced following stimulation of cells with the inflammatory cytokines interleukin-1 or tumor necrosis factor- α . Expression of CXCL5 has also been observed in eosinophils, and can be inhibited with the type II interferon, IFN- γ . This chemokine stimulates the chemotaxis of neutrophils possessing angiogenic properties. Full length CXCL5 (78 a.a.) is cleaved at the Nterminal end by cathepsin G and chymotrypsin to ENA-74 (74 a.a.) and ENA-70 (70 a.a.), with the shortened forms showing increased potency relative to full length CXCL5. CXCL5 can signal through the CXCR2 receptor.

Recombinant human ENA-78/CXCL5 (9-78 a.a.) produced in *E. coli* is a single non-glycosylated polypeptide chain containing 70 amino acids. A fully biologically active molecule, rhENA-78/CXCL5 (9-78 a.a.) has a molecular mass of 7.7 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.

Source: *E. coli*

Biological Activity: The EC₅₀ value of human ENA78/CXCL5 (9-78 a.a.) on Ca²⁺ mobilization assay in CHO-K1/G α 15/hCXCR2 cells (human G α 15 and human CXCR2 stably expressed in CHO-K1 cells) is less than 50 ng/ml.

Molecular Weight: 7.7 kDa, observed by reducing SDS-PAGE.

Formulation: Lyophilized after extensive dialysis against PBS.

Reconstitution: Reconstituted in ddH₂O or PBS at 100 μ g/ml.

Purity: > 95% as analyzed by SDS-PAGE.

Endotoxin Level: < 0.2 EU/ μ g, determined by LAL method.

Storage: Lyophilized recombinant human ENA78/CXCL5 (9-78 a.a.) remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, human ENA78/CXCL5(9-78) should be stable up to 1 week at 4°C or up to 2 months at -20°C.